Phase II evaluation of didemnin B in advanced adenocarcinoma of the kidney
- 1 March 1992
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 10 (1) , 55-56
- https://doi.org/10.1007/bf01275484
Abstract
The Southwest Oncology Group studied the response rate and toxicity of didemnin B (3.47 mg/m2 i.v. q 28 days) in patients with advanced renal cell carcinoma. There were no responses in 22 response evaluable patients. Toxicity was significant with 10 patients having grade 3 or 4 toxicity. Toxicity seen included nausea and vomiting, exacerbation of coronary artery disease, hyperglycemia, anorexia, diarrhea and hepatitis. Didemnin B was toxic but inactive in patients with renal cell treated at this dose.Keywords
This publication has 2 references indexed in Scilit:
- Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptideEuropean Journal of Cancer and Clinical Oncology, 1988
- Didemnins: Antiviral and Antitumor Depsipeptides from a Caribbean TunicateScience, 1981